{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:41:28Z","timestamp":1790700088429,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy in the past decade and amplify T-cell-mediated immune responses by disrupting immunoinhibitory signals. The augmented T-cell immune response has led to a range of immune-related adverse effects (irAEs). Immune-related cardiotoxicity has been reported in case series but has been underappreciated due to difficulties in diagnosis. This article describes epidemiological, clinical presentation, subtype, and treatment data and a new systematic framework for the clinical management of cardiotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were extracted for cancer patients who received ICIs in a single center between January 1, 2020, and February 28, 2022. ICI-associated cardiotoxicity was clinically diagnosed based on clinical presentations, biochemical biomarkers, and imaging features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified a total of 12 (2.46%) cases of ICI-related cardiotoxicity from 487 patients who received PD-1 or PD-L1 inhibitors. All patients were diagnosed with advanced or metastatic solid tumors. The severity of ICI-related cardiotoxicity ranged from subclinical cardiac abnormalities (subclinical type) with only asymptomatic troponin-I (TnI) elevations (25.0%) to symptomatic cardiac abnormalities (clinical type) (75.0%). Patients with symptomatic cardiac abnormalities had several manifestations, including tachyarrhythmia (16.7%), bradyarrhythmia (41.7%), or cardiac failure (8.3%). The median immunotherapy exposure time was 1.5 doses (range: 1 to 5), and the median time from the initial immunotherapy to the onset of ICI-related cardiotoxicity was 33.5 days (IQR: 20.3 to 46.8). Most patients, including those with subclinical cardiac abnormalities, were administered systemic corticosteroids (58.3%). One (8.3%) patient was put on mechanical ventilation, one (8.3%) received plasma exchange therapy, one (8.3%) was implanted with a pacemaker, and one (8.3%) was admitted to the ICU. Three patients with symptomatic cardiac abnormalities (25.0%) died, and other patients presented with significant clinical improvement with good outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ICI-related cardiotoxicity is uncommon but critical with a high mortality rate and poor prognosis, especially for a small group of patients with symptomatic cardiac abnormalities. More attention should be given to cardiotoxicity associated with ICIs, and these patients should be given baseline examinations and biochemical analyses before and after the initiation of immunotherapy, intensive cardiac assessments, an accurate and rapid diagnosis, and timely multidisciplinary management with immunosuppressive agents and other necessary clinical interventions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1093383","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T04:50:06Z","timestamp":1680756606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience"],"prefix":"10.3389","volume":"10","author":[{"given":"Junjuan","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baocheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: aSCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2169\/internalmedicine.5412-20","article-title":"Asymptomatic immune checkpoint inhibitor-associated myocarditis","volume":"60","author":"Tanabe","year":"2021","journal-title":"Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"950801","DOI":"10.3389\/fmed.2022.950801","article-title":"Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: a case report and review of the literature","volume":"9","author":"Yin","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: jACC: cardioOncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-020-01002-w","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: clinical risk factors","volume":"23","author":"Pirozzi","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40959-021-00106-x","article-title":"Cheng FA retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors","volume":"7","author":"Lal","year":"2021","journal-title":"Cardiooncology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome","volume":"3","author":"Geisler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.jcmg.2017.12.008","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance in acute myocarditis: a systematic review and meta-analysis","volume":"11","author":"Kotanidis","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s00392-018-1244-0","article-title":"Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices","volume":"107","author":"Pastori","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/ijms21072399","article-title":"Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro","volume":"21","author":"Tay","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.amjcard.2018.01.005","article-title":"Diagnosis and management of stress-induced cardiomyopathy in cancer patients","volume":"121","author":"Abdelghany","year":"2018","journal-title":"Am J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-Like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","article-title":"Predictive biomarkers of immune checkpoint inhibitors-related toxicities","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"879900","DOI":"10.3389\/fimmu.2022.879900","article-title":"Multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the Spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart failure and atrial fibrillation, like fire and fury","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B33","doi-asserted-by":"publisher","first-page":"969942","DOI":"10.3389\/fcvm.2022.969942","article-title":"Cardiovascular adverse events induced by immune checkpoint inhibitors: a real world study from 2018 to 2022","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1536\/ihj.21-653","article-title":"Asymptomatic myocarditis with mild cardiac marker elevation following nivolumab-induced myositis","volume":"63","author":"Shindo","year":"2022","journal-title":"Int Heart J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"884776","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurheartj\/ehq456","article-title":"Troponin elevation in coronary vs. Non-coronary disease","volume":"32","author":"Agewall","year":"2011","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11886-020-01421-y","article-title":"COVID-19 and cardiovascular health among patients with cancer","volume":"22","author":"Palaskas","year":"2020","journal-title":"Curr Cardiol Rep"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1093383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T04:50:08Z","timestamp":1680756608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1093383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2023.1093383"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1093383","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"article-number":"1093383"}}